Browse the evidence

Total energy expenditure (TEE) and activity energy expenditure (AEE) exhibit greater male variability (GMV) that peaks in young adulthood and declines in old age, whereas basal energy expenditure (BEE) and standard morphometrics (height, fat-free mass) do not follow this specific life-course pattern.

Energy expenditure is not a fixed number but a variable trait that differs significantly between individuals, especially men during their reproductive years. This variability is driven by complex interactions of activity, muscle mass, and other traits, not just basal metabolic rate or height. For health planning, individualized assessment of energy needs is more critical than relying on population averages, particularly for young adult males.

Current anti-obesity medication (AOM) studies frequently misrepresent skeletal muscle mass (SMM) loss by using DXA or BIA to estimate fat-free mass (FFM) or lean mass, which includes bone and non-skeletal tissues, thereby confounding the assessment of clinically significant muscle loss.

When reading studies on weight loss drugs (like GLP-1 agonists) that report 'muscle loss' based on DXA or bioimpedance scales, recognize that these numbers likely overestimate true skeletal muscle loss because they include bone and water. True muscle loss is likely lower than reported in these specific studies. Look for studies using MRI or CT for accurate skeletal muscle quantification.

Semaglutide promotes sex-dependent adipose tissue remodeling, with females showing more pronounced reductions in visceral fat mass and greater potency in locomotor activity increases compared to males.

Men and women may respond differently to semaglutide. This study suggests women might experience greater reductions in visceral fat and larger increases in physical activity compared to men at similar doses. This highlights the importance of sex-specific considerations in obesity treatment.

Incretin-based anti-obesity medications (GLP-1 and GIP/GLP-1 receptor agonists) cause gastrointestinal adverse effects (nausea, diarrhea, constipation) in 65–84% of patients, primarily through delayed gastric emptying and central appetite signaling activation.

If you start a GLP-1 or GIP medication, expect stomach issues like nausea or diarrhea in the first few weeks. This is very common (affecting up to 84% of users). To manage it, start with a low dose and increase slowly. Eat small, low-fat meals, stay hydrated, and avoid spicy or fatty foods. Most symptoms improve as your body adjusts.

Rapid weight loss, whether from very-low-calorie diets or bariatric surgery, significantly increases the risk of gallstone formation (cholelithiasis) due to bile supersaturation and reduced gallbladder motility.

If you lose weight very quickly (e.g., through surgery or extreme dieting), you are at higher risk for gallstones. To prevent this, aim for gradual weight loss. If you have had bariatric surgery, doctors often prescribe Ursodeoxycholic acid (UDCA) for 6 months to prevent gallstones.

Administering GLP-1 receptor agonists (liraglutide or semaglutide) during the proestrus/estrus (P/E) phase of the estrous cycle significantly enhances food intake suppression and body weight loss compared to administration during the metestrus/diestrus (M/D) phase in female rats.

If you are using a GLP-1 medication like semaglutide or liraglutide, your body's natural hormonal cycle may affect how well it works. This research suggests that taking your dose during the weeks when estrogen is highest (typically the first half of the cycle) might lead to greater appetite suppression and weight loss than taking it during other weeks. While more research in humans is needed, you might consider discussing cycle-timing with your provider to see if optimizing the timing of your injections could enhance your results.

The 'obesity paradox' in heart failure—where overweight/obese patients have better short-term outcomes than normal-weight patients—is likely confounded by unintentional weight loss from underlying diseases (like cancer) and lead-time bias, rather than being a true protective effect of obesity.

Do not rely on the 'obesity paradox' to avoid weight management. The idea that being overweight helps heart failure is likely a statistical error caused by sick people losing weight unintentionally. Intentional weight loss is associated with better clinical outcomes.

Inhibiting PCSK9, NF-κB, and NLRP3 reduces cholesterol and inflammation, providing cardioprotection.

For cardiovascular protection, medications that lower cholesterol (like PCSK9 inhibitors) and reduce inflammation (targeting NF-κB or NLRP3) are effective strategies. These treatments help manage risk factors associated with heart disease and metabolic disorders. Discuss with your healthcare provider if these targeted therapies are suitable for your cardiovascular health.

Dulaglutide, subcutaneous semaglutide, and tirzepatide exhibit comparable risks of severe gastrointestinal adverse events (including acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation) in adults with type 2 diabetes.

If you are choosing between dulaglutide, semaglutide, or tirzepatide for type 2 diabetes, do not expect a significant difference in the risk of serious stomach problems (like pancreatitis or bowel obstruction) between them. They all carry a similar, low risk of severe GI events, though mild nausea or diarrhea is common with all. Your choice should likely be based on efficacy (weight loss/glycemic control), cost, and tolerability of mild side effects rather than fear of severe GI complications.

There are significant research gaps regarding the effectiveness of nutritional interventions for underrepresented populations, specifically women, older adults, and Asian populations.

Be aware that most research on muscle hypertrophy interventions focuses on men and Western populations. If you are a woman, older adult, or from an Asian background, the optimal nutritional strategy may differ, and you should consult a professional for personalized guidance.

Obesity is a primary chronic disease driven largely by genetic predisposition, amplified by caloric intake and decreased energy expenditure, requiring recognition as a disease for proper insurance coverage and management.

Stop blaming yourself or your patients for obesity. It is a primary disease with strong genetic components. This recognition is the first step to getting proper insurance coverage and medical treatment, not just lifestyle advice.

Using external momentum (cheat repetitions) during single-joint upper body resistance training produces muscle hypertrophy equivalent to strict technique, despite generating significantly higher volume load.

If you are doing single-joint exercises like bicep curls or tricep pushdowns, you don't need to be rigid about 'strict' form to maximize muscle growth. Using 'cheat' reps (adding momentum) allows you to lift more total volume, which resulted in the same muscle growth as strict reps in this study. However, be cautious of joint stress, especially in your back and hips, as momentum can increase injury risk. Use this technique strategically, perhaps at the end of a set, rather than for every rep, to balance gains with safety.

Providing free, convenient gym access to employees does not significantly improve weight loss outcomes compared to standard behavioral interventions, as gym usage remains low and weight loss is driven by the behavioral program rather than facility proximity.

Buying a gym membership or working near a gym will not automatically make you lose weight. In this study, people who worked near the gym used it more often, but they didn't lose more weight than those who didn't. Weight loss came from the behavioral program (diet/lifestyle coaching), not the gym access itself. Focus on the behavioral changes (diet, activity habits) rather than just buying access to facilities.

High carbohydrate intake (highest tertile, median 59.3% energy) is associated with increased MRI-detected vascular brain injury (covert brain infarcts and white matter hyperintensities) and lower cognitive scores (MoCA and DSST) in middle-aged adults.

If you are middle-aged and concerned about brain health, look at your overall macronutrient balance. High carbohydrate intake (over 59% of calories) is linked to more silent brain injuries and lower cognitive scores. Try shifting some of those carbohydrates to healthy fats, like those found in nuts, olive oil, or fish, which were associated with better brain health in this study.

Bariatric surgery (RYGB or SG) improves peripheral insulin sensitivity only after substantial weight loss (>30%) is achieved at 1 year, whereas low-calorie diet (LCD) fails to improve insulin sensitivity despite initial weight loss, indicating that the magnitude of weight loss, not the surgical mechanism itself, drives late-stage insulin sensitivity improvements.

If you undergo bariatric surgery, do not expect immediate improvements in insulin sensitivity. The metabolic benefits, such as improved insulin sensitivity, typically take about a year to manifest and are directly tied to the amount of weight you lose. If you do not lose significant weight, your insulin sensitivity may not improve, regardless of the surgery type.

Obesity promotes cancer development by increasing DNA damage and impairing DNA repair mechanisms, while simultaneously activating pro-survival signaling pathways that prevent the elimination of damaged cells.

Maintaining a healthy weight is a critical strategy for reducing cancer risk, not just for metabolic health. Obesity creates a biological environment that damages DNA and prevents the body from fixing those damages, while also protecting damaged cells from dying. Weight management interventions should be viewed as a direct cancer prevention strategy.

Periconceptional exposure to GLP-1 receptor agonists (liraglutide or semaglutide) is associated with an increased risk of preterm birth, but this risk is confined to women using the medication for diabetes treatment and is not observed in women using it for weight management.

If you are using a GLP-1 medication (like Ozempic or Saxenda) and planning pregnancy, talk to your doctor. If you have diabetes, the increased risk of early delivery is likely due to the diabetes, not the drug, so managing your blood sugar is key. If you are using it for weight loss, current large-scale data shows no increased risk of early delivery, which may help alleviate anxiety about inadvertent exposure.

Current herbal anti-obesity clinical trials frequently fail to adhere to international pharmaceutical guidelines, particularly regarding study duration, lifestyle modifications, and safety monitoring.

When evaluating herbal weight loss studies, be aware that many do not follow the same rigorous standards as pharmaceutical trials. Look for studies that include lifestyle modifications, adequate duration, and safety monitoring, as these are often missing.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides vasculoprotective and anti-atherosclerotic benefits by stimulating endothelial progenitor cell mobilization, enhancing nitric oxide synthase activity, and suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

If you have Type 2 Diabetes or obesity with cardiovascular risk factors, Tirzepatide is not just a weight-loss drug. It actively protects your blood vessels by improving endothelial function and reducing inflammation. The standard protocol starts at a low dose (2.5 mg) once weekly and titrates up to 15 mg based on tolerance and glycemic goals. It is administered via subcutaneous injection alongside lifestyle changes.

Current incretin-based therapies (GLP-1 and GLP-1/GIP agonists) primarily reduce body weight through decreased food intake, but they fail to increase energy expenditure (EE) and often cause a compensatory drop in basal metabolic rate, which hinders sustainable weight loss.

If you are using GLP-1 medications like semaglutide or tirzepatide, expect significant weight loss primarily from eating less, not from burning more calories. Be aware that your body will likely slow down its resting metabolism as you lose weight, which can make maintaining loss difficult. This is a known biological adaptation, not a personal failure. Future treatments may combine appetite suppression with energy expenditure boosting to overcome this.

Hypoglycemia occurs in approximately 9% of GLP-1/GIP RA emergency exposures, a rate higher than previously reported, even in the absence of concomitant hypoglycemic medications.

Be aware that GLP-1 medications can cause low blood sugar, even if you aren't taking insulin. This is more likely if you skip meals, exercise heavily, or take a higher dose. Monitor your blood sugar if you feel shaky, dizzy, or confused, and treat lows with fast-acting carbohydrates.

Post-exercise consumption of 25g collagen hydrolysate or dairy protein does not improve indices of exercise-induced muscle damage (EIMD) or accelerate recovery compared to an isoenergetic placebo in recreationally active males.

If you are doing intense eccentric exercise (like downhill running), drinking 25g of collagen or dairy protein immediately after and for the next two days will not speed up your recovery or reduce soreness any more than drinking a placebo with the same calories. Focus on total daily protein intake and sleep rather than timing specific recovery supplements.

In older adults, visceral fat levels significantly decrease over two years, while body weight, muscle mass, and total body fat percentage do not change significantly.

As you age, your visceral fat may naturally decrease even if your weight and muscle mass stay the same. This highlights the importance of monitoring visceral fat, not just weight.

Bone Mineral Content (BMC) continues to decline during the weight regain phase (6-12 months) even when total body weight and fat mass are increasing.

If you lose a significant amount of weight (5% or more), your bone density may drop. This drop can continue even if you regain some of the weight later. To protect your bones, consider baseline bone density assessments if you are at risk (e.g., postmenopausal women) and ensure adequate calcium and vitamin D intake alongside resistance training.